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Abstract 
Background: Recent studies on migraineurs and our own animal experiments have revealed 
that pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) has an important role 
in activation of the trigeminovascular system. The aim of this study was to determine the 
PACAP-38-like immunoreactivity (LI) in the plasma in healthy subjects, and parallel with the 
calcitonin gene-related peptide (CGRP)-LI in migraine patients in the ictal and interictal 
periods.  
Methods: 87 migraineurs and 40 healthy control volunteers were enrolled in the examination. 
Blood samples were collected from the cubital veins in both periods in 21 patients, and in 
either the ictal or the interictal period in the remaining 66 patients, and were analyzed by 
radioimmunoassay.  
Results: A significantly lower PACAP-38-LI was measured in the interictal plasma of the 
migraineurs as compared with the healthy control group (p<0.011). In contrast, elevated 
peptide levels was detected in the ictal period relative to the attack-free period in the 21 
migraineurs (pPACAP-38<0.001; pCGRP<0.035) and PACAP-38-LI in the overall population of 
migraineurs (p<0.009). A negative correlation was observed between the interictal PACAP-
38-LI and the disease duration.  
Conclusion: This is the first study that has provided evidence of a clear association between 
migraine phases (ictal and interictal) and plasma PACAP-38-LI alterations.  
Introduction 
It is possible to analyse the mechanisms of pain in animal models, but there are no 
really clinically relevant systems to appropriately mimic the human specificity of headache 
diseases. Human investigations are therefore particularly important to identify the key 
mediators responsible for the development and progression of migraine.  
Several hypotheses have been proposed to explain the pathological mechanisms of 
migraine. One of the most widely accepted theories relates to activation of the 
trigeminovascular system (TS), which involves vascular and neuronal elements (1). The TS 
consists of the primary sensory pseudounipolar neurons in the trigeminal ganglion (TRIG), its 
terminals, and the meningeal vasculature. The peripheral afferents innervate the 
supratentorial dura mater, the dural vasculature and the large and small pial arteries on the 
surface of the brain. The central fibres project to the area of the second-order neurons in the 
brainstem, the caudal trigeminal nucleus (TNC). The third-order neurons are located in the 
thalamus. The activation mechanism involves the release of neuropeptides from the terminals 
(e.g. calcitonin gene-related peptide (CGRP), vasoactive intestinal peptide (VIP) and 
substance P (SP) (2), and functional changes such as neurogenic inflammation (protein 
extravasation and vasodilatation), mast cell degranulation and sensitization (3). 
Among the numerous “migraine-related” processes and substances, the vasoactive 
pituitary adenylate cyclase-activating polypeptide (PACAP) has been potentially implicated 
in the pathophysiology of migraine (4, 5). PACAP belongs to the VIP/secretin/glucagon 
neuropeptide superfamily, and is considered to be a “brain-gut peptide“, by virtue of its 
widespread expression and functions in the human body. PACAP exists in two forms: 
PACAP-27 and PACAP-38; the latter is expressed predominantly in mammals. PACAP acts 
at one specific (PAC1) and two non-specific receptors, which are shared between PACAP and 
VIP (VPAC1 and VPAC2). This can be explained by the 68% structural homology between 
PACAP and VIP (6-8).  
This implies that PACAP-38 also has a vasodilatating effect (9), and a broad range of data 
suggest that it is an integrator of nociceptive and sensitization processes, besides being 
involved in neurogenic inflammation (10-13).  
PACAP is presented in the primary sensory neurons of the TRIG (14), the parasympathetic 
otic and the sphenopalatine ganglia (15, 16). Moreover, PACAP-38 is found in the cell bodies 
and nerve fibres of the human TNC and the upper regions of the cervical spinal cord, which 
suggests that PACAP may be closely related to the TS (2, 17). We earlier furnished evidence 
for this hypothesis with animal experimental results. PACAP-deficient mice displayed 
reduced light-aversive behaviour (photophobia), while decreased meningeal blood flow and 
c-fos expression in the TRIG and TNC were detected relative to wild-type mice after 
nitroglycerol (NTG)-induced TS activation (18). Further, elevated levels of PACAP-27 and 
PACAP-38 were measured in the plasma and the TNC 90 and 180 min after the respective 
stimulation in two animal models of TS activation (19). These results suggest that PACAP 
may be an important mediator, and therefore a diagnostic marker of TS activation. 
The available human data point to the involvement of PACAP in the mechanisms of migraine. 
Schytz et al. demonstrated that the intravenous administration of PACAP-38 causes headache 
in healthy subjects, and migraine-like attacks in migraine patients without aura, 6 h in 
average after starting the infusion (4). However, no clinical data are available on endogenous 
alterations in PACAP levels in relation to migraine. 
Based on the literature, we have hypothesized that the plasma concentration of PACAP-38 
increases during migraine attacks. Our aims were therefore to reveal the potential 
relationships between the PACAP-38 levels of the human plasma and the presence of 
migraine headache. Radioimmunoassay (RIA) measurements were carried out in peripheral 
blood plasma samples in order to show alterations of PACAP-38-like immunoreactivity 
(PACAP-38-LI) in migraine patients during the ictal and interictal periods in comparison 
with healthy control subjects.  In addition, the clinical features of the disease, as well as 
plasma CGRP-like immunoreactivity (CGRP-LI) were also compared to the PACAP-38-LI to 
explore possible correlations.  
 
Materials and methods 
 
Participants  
87 migraine patients with or without aura and 40 healthy control subjects were enrolled in 
this study. The migraineurs were selected in accordance with the criteria of the Headache 
Classification Committee of the International Headache Society 2004 (20). The study groups 
were age-matched. The demographic and clinical characteristics of the patient and control 
populations are summarized in Table 1.  
A detailed questionnaire was used to compile a homogeneous group of migraineurs as 
concerns the features of their migraine disease: the duration of the migraine, the attack 
frequency, allodynia (21), the severity of pain during attacks as measured on a visual-
analogue scale (VAS). The relation of the migraine attacks to the menstrual cycle (22) and to 
the presence of other non-migraine, chronic pain disorder (lumbago, low-back pain, knee- 
and hip-joint arthrosis) was also assessed. Depression was not clinically diagnosed in any of 
the cases. Healthy volunteers serving as controls were screened for non-reported/non-treated 
headaches. Subjects (both patients and controls) who displayed any significant and serious 
non-migraine chronic disorders were excluded from the study. 
 
Study design and procedures 
The study was approved by the Ethics Committee of the Faculty of Medicine, University of 
Szeged (87/2009). All study participants gave their written informed consent, in accordance 
with the Declaration of Helsinki. There were no restrictions as regards food and drink intake. 
Blood samples were drawn from migraineurs during an attack and/or in an attack-free period. 
Affected patients were asked not to start their usual attack treatment until blood samples had 
been taken. Accordingly, 80 interictal and 28 ictal samples were collected. From among the 
87 patients, blood samples could be collected in both periods from 21 migraineurs. Data of 
the population of 21 migraineurs are shown in Table 2. A single blood sample was taken 
from each control. Blood samples (6 ml per subject) were taken in a sitting position during 
rest from the cubital vein and collected in ice-cold glass tubes containing the anticoagulant 
(ethylenediaminetetraacetic acid (EDTA, 12 mg) and the protease inhibitor aprotinin 
(Trasylol, 1200 IU), and kept at 4 °C until centrifugation (2000 rpm for 10 min at 4◦C). 
Plasma samples were stored at −80 °C until the PACAP-38-LI- and CGRP-LI were measured 
by RIA.  
 
RIA measurements and data acquisition 
Plasma concentrations of PACAP-38 were determined with specific and sensitive RIA 
techniques developed earlier in our laboratory (23). The PACAP-38 antiserum 88111-3 was 
raised in rabbits with synthetic peptides conjugated to bovine serum albumin (BSA) or 
thyroglobulin with glutaraldehyde or carbodiimide. The high specificity and C-terminal 
sensitivity of this antibody were confirmed by cross-reactivity studies, and no cross-reactivity 
was found with PACAP-27 or with other related neuropeptides in either case. Following 
centrifugation of the plasma samples (2000 rpm at 4 °C for 10 min), the peptide was 
extracted from the plasma into 3 volumes of absolute alcohol. 
After precipitation and a second centrifugation (2000 rpm at 4 °C for 10 min), the samples 
were dried under a nitrogen flow and resuspended in 300 µl of assay buffer before RIA 
determination in order to achieve a 10-times higher concentration for the RIA procedure (10, 
23). The tracers were mono-125I-labelled peptides prepared in our laboratory. Synthetic 
peptides were used as RIA standards in concentrations ranging from 0 to 1000 fmol/ml. The 
assay was prepared in 1 ml 0.05 M (pH 7.4) phosphate buffer containing 0.1 M sodium 
chloride, 0.25% (w/v) BSA and 0.05% (w/v) sodium azide. The antiserum (100 µl, 1:10,000 
dilution), the RIA tracer (100 µl, 5000 cpm/tube) and the standard or unknown samples (100 
µl) were measured into polypropylene tubes with the assay buffer. After incubation for 48–72 
h at 4 °C, the antibody-bound peptide was separated from the free peptide by the addition of 
100 µl of separating solution (10 g charcoal, 1 g dextran and 0.5 g commercial fat-free milk 
powder in 100 ml of distilled water). Following centrifugation (3000 rpm at 4 °C for 15 min), 
the contents of the tubes were gently decanted and the radioactivity of the precipitates was 
measured in a gamma counter (Gamma, type NZ310). The PACAP-38 concentrations of the 
unknown samples were read from calibration curves. 
 
Statistical analysis 
Data expressed as means ± SD if not stated otherwise. The normality of the data was tested 
with the Shapiro-Wilk test. Group comparisons were carried out with the Student’s unpaired, 
paired t-tests and the Wilcoxon-test with SPSS 17.0. Data were analysed with multivariate 
test (repeated measure ANOVA) in the case of menstruation cycle and chronic pain condition 
related to PACAP-38 level. Statistical significance was accepted at p<0.05. 
 
Results  
Differences in plasma PACAP-38-LI between migraineurs and healthy controls  
As concerns the total of 87 migraine patients (n=87), a significantly lower PACAP-38-LI was 
determined in the interictal plasma of the migraineurs (n=80; 24.60±3.59 fmol/ml) than in 
that of the healthy volunteers (n=40; 26.54±4.43 fmol/ml; Student’s unpaired t-test, p<0.011, 
t=2.578) (Fig. 1/A). However, the plasma samples from the patients during their migraine 
attacks (n=28) exhibited a significantly higher PACAP-38 concentration (27.39±4.67 
fmol/ml) as compared with the interictal samples (n=59; 24.91±3.73 fmol/ml; Student’s 
unpaired t-test, p<0.009, t=-2.676) (the interictal data of those 21 migraineurs whose plasma 
samples were collected from both periods were excluded from this analysis to avoid the 
statistical problems caused by the paired samples) (Fig. 1/B). No difference was found when 
the ictal samples were compared with those of the controls (Student’s t-test for unpaired 
comparisons, p<0.447, t=-0.765) (Fig. 1/C).  
 
Association between plasma PACAP-38-LI and duration of migraine  
A negative correlation was found between the duration of the migraine and the interictal 
PACAP-38-LI (n=87; linear regression, p<0.044, R=0.231) (Fig. 2). Plasma PACAP-38-LI 
did not correlate with the age, attack frequency, allodynia, and the VAS-score (ANOVA, 
linear regression, p>0.05) or differences were not found regarding the gender, hormonal 
changes and pain (Student’s unpaired t-test, p>0.05). 
 
Changes in plasma PACAP-38-LI and CGRP-LI in 21 migraineurs 
To gain insight into the changes of neuropeptide levels, we measured the plasma 
concentrations of PACAP-38 and CGRP plasma concentration in the same subject during a 
headache attack and interictally. The plasma PACAP-38-LI was significantly higher in the 
ictal period (28.04±5.00 fmol/ml) than in the interictal period (23.74±3.09 fmol/ml) (n=21; 
Student’s paired t-test, p<0.001, t=-4.134) (Fig. 3/A).  
The CGRP-LI was determined simultaneously with the PACAP-38-LI in both phases in 18 
migraineurs. Significantly higher CGRP levels were observed in the plasma samples during 
the ictal period (53.74±31.52 fmol/ml) as compared with the interictal period (39.74±27.49 
fmol/ml) (n=18; Wilcoxon-test, p<0.035) (Fig. 3/B).  
Associations of changes in plasma PACAP-38-LI with the menstruation cycle sensitivity and 
chronic pain conditions in 21 migraineurs   
Changes in the plasma PACAP-38-LI proved to be influenced by 2 parameters: There was a 
significant PACAP-38-LI elevation in the ictal phase (31.01±3.32) compared to the interictal 
phase (24.18±2.52) in patients whose migraine headache was not sensitive to the 
menstruation cycle (Group 1: n=11; Student’s paired t-test, p<0.00002, t=-7.250). Meanwhile, 
there was no such significant increase during the ictal phase (24.78±4.56) compared to the 
interictal phase (23.26±3.70) in patients whose migraine headache was sensitive to the 
menstruation cycle (Group 2: n=10; Student’s paired t-test, p<0.344, t=-0.998) (Fig. 4).  
Similar PACAP-38-LI increase was detected in the ictal phase (30.01±3.69) vs. the interictal 
phase (24.15±2.47) of patients, who did not have chronic pain-related conditions (Group 1: 
n=15; Student’s paired t-test, p<0.00005, t=-5.716). However, there was no difference in the 
ictal phase (23.13±4.64) compared to the interictal phase (22.71±4.40) in patients, who had 
other non-migraine, chronic pain disorders (Group 2: n=6; Student’s paired t-test, p<0.833, 
t=-0.222) (Fig. 5).  
To reveal the relationship between ictal-interictal PACAP-38 levels and mentruation and 
chronic pain, repeated measure ANOVA was used. Multivariate test showed significant main 
effect of PACAP-38 measurements in different phases of the disease (F(1,19)=22.579, 
p<0.0001) and main effect of headache related to the menstruation cycle (F(1,19)=22.257, 
p<0.0001). The interaction of the two factors was also significant (F(1,19)=9.096, p<0.007). 
Similar ANOVA was carried out for identifying if ictal/interictal PACAP-38 level changes 
are influenced by concomitant chronic pain conditions. While significant main effects were 
identified by analysis (ictal/interictal: F(1,19)=11.392, p<0.003, chronic pain condition: 
F(1,19)=0.553, p<0.446) the interaction was not significant in this case (p>0.05).  
No correlations were found between the level of peptides and age, gender, the attack 
frequency, allodynia or the VAS-score. 
 
Discussion 
This study provided the first evidence that the PACAP-38 concentration in the plasma 
of migraineurs is significantly lower in the interictal period as compared with that in healthy 
volunteers, but increases during migraine attacks relative to the attack-free period. These 
results suggest that PACAP-38 might be an important mediator of the pathophysiology of 
migraine. The difference in the plasma levels of PACAP-38 in migraineurs in the two periods 
indicate that this peptide is involved in the development of the attacks.  
Effects of PACAP-38 related to migraine  
PACAP-38 can be released from both the central and the peripheral terminals of the 
pseudounipolar neurons of the TRIG (24) in response to specific triggers. It enters the 
systemic circulation, and binds to its receptors (PAC1, VPAC1 and VPAC2) on the meningeal 
vessels and second-order sensory neurons. Zagami and co-workers published (25) that the 
stimulation of the superior sagittal sinus causes extracranial release of PACAP. PACAP is 
known to induce neurogenic inflammation, mast cell degranulation, neuronal activation and 
sensitization (4, 26). These effects can contribute to the development of severe headache and 
possibly to aggravation of the attacks.  
An MRI angiographic study revealed that PACAP-38 infusion-induced headache is related to 
significant dilatation of the middle meningeal arteries (MMAs), in contrast with the middle 
cerebral arteries (27). The intracarotid infusion of PACAP-38 produces significant dilatation 
of the dural artery in the rat, and this administration route has proved to be more effective 
than the intravenous mode (28). PACAP-38 also exerts potent vasodilating action on 
pressurized MMAs, which can be influenced by a PAC1 receptor antagonist. Multiple 
variants of the PAC1 receptor have been found besides the VPAC2 receptors in the rat MMAs 
(29).  
PACAP and VIP receptors in the human meningeal and coronary arteries were recently 
characterized with pharmacological modulators, and these peptides were found to have lower 
potency and efficacy in meningeal vasculature than in coronary arteries. This study 
concluded that processes of PACAP-38-induced migraine-like headache may not involve 
meningeal vasodilatation rather than sensitization of peripheral and central sensory trigeminal 
fibres (9). The reported effects of a PACAP infusion regarding neurogenic inflammation and 
mast cell degranulation in relation to migraine are controversial (26). It was concluded from a 
study of the mast cell degranulating effects of different truncated PACAP and VIP fragments 
on rat peritoneal and dural mast cells that phospholipase C-mediated mast cell degranulation 
is implicated in PACAP-induced migraine (30). 
 
Possible mechanisms related to the elevated PACAP-38-LI during migraine attacks 
There are some anatomical and physiological factors, which might be involved in the 
migraine-like headache inducing effect of PACAP-38.  
A.)  PACAP-38 is a sensory (14), sympathetic (15) and parasympathetic (16) neuropeptide 
(31), which is released from the nerve endings (2, 14, 17, 32) at the dural or other cranial 
compartments. It can modulate both vessels and nerve fibres through its receptors leading to 
elevated intracellular cyclic adenosine monophosphate (cAMP) levels (33). There are several 
lines of evidence that the increased cAMP cause sensitization and activation of the trigeminal 
neurons (34) and meningeal nociceptors (35, 36), therefore induce delayed headache (37).  
The headache-inducing action of PACAP-38 was first described in 2009 by Schytz and co-
workers, who demonstrated that PACAP-38 has a simple headache-evoking effect in healthy 
volunteers, but provokes severe migraine-like attacks in susceptible subjects. A decreased 
mean blood flow velocity in the middle cerebral artery and an increase in diameter of the 
superficial temporal artery were observed 20 min following the infusion (4). It is possible that 
that PACAP-38 has a positive feedback, self-amplifying effect, which can contribute to the 
maintenance and aggravation of the headache.  
Based on similar features and receptors of PACAP and VIP, as well as the supposed complex 
mechanism of migraine, it is likely that migraine cannot be related only to PACAP-38. Its 
causative role is equivocal, but its involvement is unquestioned.  
This peptide can contribute to the evolution of migraine attacks in co-operation with other 
regulatory neuropeptides, molecules and enzymes, like VIP, CGRP, 5-HT, SP and NO. When 
the headache starts in response to specific triggers (vasodilatation – plasma protein 
extravasation - mast cell degranulation - neuropeptide release - neurogenic inflammation) the 
presence and aggravation of pain may lead to the release of PACAP-38 from the nerve 
terminals, as a self-triggering process. This can be an explanation for the finding that the 
increase of plasma PACAP-38-LI in the ictal phases of migraineurs compared to the interictal 
one is moderate, but significant. 
B.)  Numerous studies have approached the effects of PACAP-38 involved in headache 
from vasodilating aspects. There are controversial result regarding the relaxing actions of 
PACAP-38 on meningeal or cerebral, arteries (9, 29, 38, 39). The vasodilating properties in a 
small extent or indirectly is likely to contribute to the development of the headache, e. g. 
PACAP induces vascular effects mediated via activation of perivascular nerves (40). The 
vascular effects cannot be excluded, but based on the literature it seems that these may be less 
relevant in migraine (9). PACAP-38 is more potent to sensitize trigeminal peripheral sensory 
fibres directly and also through mast cell degranulation (4, 26, 30). These mechanisms can be 
related to the phenomenon of throbbing headache, which can correlate with the increased 
PACAP-38-LI during the ictal phase of migraineurs found in our study. Subsequently, it 
would be plausible that the activation of the second order trigeminal neurons by PACAP-38 
can result in a direct central sensitization (4).    
 
Complementary mechanisms behind reduced PACAP-38-LI during interictal phase of 
migraine patients 
The lower concentration of PACAP-38 observed in the interictal period, and 
especially the correlation of the interictal plasma PACAP-38-LI with the disease duration, 
might be explained indirectly in terms of brain energy deficit (an impairment of the cerebral 
and striated muscle energy metabolism (41, 42), elevated lactate levels (43, 44), 
abnormalities of mitochondrial compartments (45) and imbalanced Mg2+ concentration in the 
neurons (46, 47) ). 
It may additionally be hypothesized that the low interictal peptide concentration might 
be associated with degenerative changes affecting the PACAP-releasing circuitries (cortical 
atrophy (48), iron deposition in the periaqueductal grey matter (49), and increased levels of 
markers indicative of neuronal and glial damage (50)).  
 
The possible role of the blood-brain barrier (BBB) 
The ability of PACAP to pass through the intact BBB is limited; it needs specific transporters 
in specific brain areas (51, 52). However, the enhanced BBB permeability in migraine may 
allow PACAP to penetrate into the cerebrospinal fluid and exert its central effects. From the 
opposite aspect, the PACAP released in the brain (6) can also penetrate through the BBB, and 
hence may be detected in the plasma. There are assumptions that the integrity of the BBB is 
disrupted in migraineurs (53, 54). A transient brain dysfunction, vasogenic cerebral oedema 
and a damaged BBB can develop in lipopolysaccharide-induced brain injury in rats in 
response to the over-expression of matrix metalloproteinase 9 (55). This enzyme can degrade 
the basal membrane, resulting in structural impairment of the BBB, and altered plasma levels 
of which have been observed in patients with migraine (56-59).  
 
Correlation of PACAP-38-LI with the menstruation cycle and other chronic pain conditions 
in migraineurs 
Migraine attacks are often closely related to female hormonal changes (22). Hence, it 
is interesting that PACAP-38-LI increases significantly during the ictal period only in those 
women whose headache is not related to the menstrual cycle. Although, the influence of the 
menstruation cycle in the PACAP-38-LI changes cannot be excluded, but there is evidence 
that the plasma concentration of PACAP-38 is relatively stable and independent of the gender, 
age, food intake or female hormonal cycles in healthy subjects (60).  
It is well established that PACAP-38 plays an important role in a variety of other pain 
conditions (61-63). In opposition there was no increased PACAP-38 LI in the ictal phase in 
patients with other chronic pain conditions. Moreover, we did not find any statistical proof of 
the influence of the chronic pain and the alterations of the PACAP-38 level. 
 
Possible relations between the PACAP-38 and CGRP in migraineurs 
More than 20 years ago, the release of CGRP was demonstrated in the extracerebral 
circulation of humans and cats in response to TS activation (64, 65). CGRP-containing 
neurons have been detected in the human TRIG (14, 66) and elevated plasma CGRP levels 
have been described in migraine (67, 68) and other types of primary headache (69). Moreover, 
an intravenous infusion of human alpha-CGRP causes migraine headache (37, 70) and there 
is a significant positive correlation between plasma levels of CGRP and headache severity 
scores in NTG-induced migraine attacks (71). However, one controversial study questions the 
importance of CGRP in migraine (72). In fact, CGRP-receptor antagonists are effective in the 
treatment of migraine disorder (73), but their side-effect profile, with special emphasis on 
hepatotoxicity, currently makes this drug development direction problematic (74-76). Our 
results draw attention to a possible influence between the PACAP and CGRP systems in 
migraine pathogenesis.  
 Conclusions 
It is concluded that PACAP-38 might be implicated in the development of migraine 
headache. There is association between migraine periods (ictal and interictal) and alterations 
in PACAP-38 levels in the plasma. The quantitative changes in this peptide in the plasma are 
related to the disease duration, the menstruation cycle and the presence of other pain-related 
disorders.  The causative role of PACAP-38 in migraine headache demands further studies. 
Our results indicate the need for investigations of the role of plasma PACAP-38 as a putative 
biomarker of migraine, which might provide new perspectives as concerns the identification 
of a new target in the therapy of migraine. 
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Table and Figure legends 
 
Table 1: Mean data on healthy control volunteers and 87 migraineurs (age, gender, type of 
migraine (with or without aura), disease duration (years), attack frequency, allodynia, and 
VAS-score are shown. MA: migraine with aura; MO: migraine without aura. Allodynia: 0: 
absence of allodynia; 1: mild allodynia; 2: moderate allodynia; 3: serious allodynia.   
 
Table 2: Demographic data on 21 migraineurs, whose samples from both the ictal and the 
interictal periods were analysed. The age, gender, type of migraine (with or without aura), 
disease duration (years), attack frequency, allodynia, VAS-score, PACAP-38-LI in plasma 
samples (fmol/ml) originating from interictal and ictal phases, the time of the previous attack 
before interictal blood sampling (days) and the duration of the present headache (hours) are 
shown for each patient. MA: migraine with aura; MO: migraine without aura. Allodynia: 0: 
absence of allodynia; 1: mild allodynia; 2: moderate allodynia; 3: serious allodynia   
 
 
 
 
Fig. 1: PACAP-38-LI (fmol/ml) was determined by RIA in the plasma of the migraineur 
groups in comparison with those of healthy volunteers. Boxes indicate PACAP-38-LI 
(median±SD, minimum and maximum values) of healthy control subjects (n=40), and of 
migraineurs (n=87) during the interictal (n=80) and ictal periods (n=28). Significant PACAP-
38-LI decrease was observed between the control vs. the interictal group with Student’s 
unpaired t-test, p<0.011 (A). To except the interictal data of the paired samples, the interictal 
(n=59) vs. the ictal (n=28) group comparison showed significantly higher PACAP-38-LI 
during migraine attacks with Student’s unpaired t-test, p<0.009 (B). There were no 
significant PACAP-38-LI differences between the control and the ictal group with Student’s 
t-test for unpaired comparisons, p<0.447 (C). 
 
 
 
 
Fig. 2: Interictal plasma PACAP-38-LI (fmol/ml) depending on the duration of the migraine 
disorder in the group of migraineurs (n=87). A negative correlation was observed with linear 
regression on the graph, p<0.044. 
 
Fig. 3: PACAP-38-LI (fmol/ml) was determined by RIA on plasma samples from 
migraineurs in both interictal and ictal periods. A: Plots of individual data for each patient. A 
significant difference was observed between the levels in the two phases with Student’s 
paired t-test, p<0.001. 
CGRP-LI (fmol/ml) was determined by RIA on plasma samples from migraineurs in both 
interictal and ictal periods. B: Plots of individual data for each patient (n=18). A significant 
difference was observed between the levels in the two phases with Wilcoxon-test, p<0.035. 
The thick grey lines represent the mean values. 
 
Fig. 4: Plasma PACAP-38-LI (fmol/ml) in the interictal and ictal periods of two 
subpopulations of 21 migraineurs, characterized on the basis of the menstruation cycle 
dependence. Group 1: menstruation cycle-independent migraineurs (n=11); group 2: migraine 
patients, whose headache was sensitive to their menstruation (n=10). Each box represents the 
median±SD, minimum and maximum values of the results. A significant difference in 
PACAP-38-LI was observed between the interictal and ictal phases in group 1 with Student’s 
paired t-test, p<0.00002. 
 
Fig. 5: Plasma PACAP-38-LI (fmol/ml) in the interictal and ictal periods of two 
subpopulations of 21 migraineurs characterized on the basis of chronic pain conditions. 
Group 1: patients without chronic low back pain (n=15); group 2: patients with simultaneous 
low back pain (n=6). Each box represents the median±SD, minimum and maximum values of 
the results. A significant difference in PACAP-38-LI was observed between the interictal and 
ictal phases in group 1 with Student’s paired t-test, p<0.00005. 
 
Article Highlights 
1. The PACAP-38 has an important role in the mechanisms of migraine attack. 
2. A significantly lower PACAP-38 concentration in the interictal plasma of the 
migraineurs as compared with the healthy controls is associated with the duration of 
migraine disease.   
3. The elevated plasma PACAP-38 level in the ictal phase relative to the attack-free 
period is attributable to the releasing peptide from the PACAP-containing neurons, 
which can contribute to the development and/or the aggravation of migraine attacks.  
 
